cancer.duke.edu/btc  
The Preston Robert Tisch Brain Tumor Center at Duke

Leadership/Faculty/Staff

Faculty and Staff

Sridharan Gururangan, MRCP (UK) 

Sridharan Gururangan, MRCP (UK)
Director of Pediatric Clinical Services
Associate Professor of Pediatrics
Associate Professor of Surgery

Duke University Medical Center
DUMC Box 3624
Durham, NC  27710
Tel: (919) 684-3506
Fax: (919) 668-2485
Email: gurur002@mc.duke.edu

Dr. Gururangan is a pediatric neuro-oncologist responsible for designing and providing care to children with brain and spinal cord tumors. Dr. "Sri" Gururangan focuses exclusively on the clinical care of children with brain tumors. Over the last 10 years, he has had extensive experience in the treatment of children with cancers, particularly brain tumors, in several premier institutions in the United States, England, Ireland, and most recently at Memorial Sloan-Kettering Cancer Center in New York. He designs clinical protocols, which utilize the newest advances in the treatment of children with these tumors.

  Dr. Gururangan's CV

Recent Publications

Fouladi M,Gururangan S,Moghrabi A,Phillips P,Gronewold L,Wallace D,Sanford RA,Gajjar A,Kun LE,Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.,7/15/2009, (3243-53) - Cancer Abstract [More ...]

Quinn JA,Jiang SX,Reardon DA,Desjardins A,Vredenburgh JJ,Gururangan S,Sampson JH,McLendon RE,Herndon JE 2nd,Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.,7/1/2009, (2964-70) - Cancer Abstract [More ...]

Reardon DA,Desjardins A,Vredenburgh JJ,Gururangan S,Friedman AH,Herndon JE 2nd,Marcello J,Norfleet JA,McLendon RE,Sampson JH,Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.,6/28/2009, (-) - Journal of neuro-oncology Abstract [More ...]

Quinn JA,Jiang SX,Reardon DA,Desjardins A,Vredenburgh JJ,Rich JN,Gururangan S,Friedman AH,Bigner DD,Sampson JH,McLendon RE,Herndon Jr JE,Walker A,Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.,3/16/2009, (-) - Neuro-oncology Abstract [More ...]

Quinn JA,Jiang SX,Reardon DA,Desjardins A,Vredenburgh JJ,Rich JN,Gururangan S,Friedman AH,Bigner DD,Sampson JH,McLendon RE,Herndon JE 2nd,Walker A,Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.,3/10/2009, (1262-7) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]

Reardon DA,Egorin MJ,Desjardins A,Vredenburgh JJ,Beumer JH,Lagattuta TF,Gururangan S,Herndon JE 2nd,Salvado AJ,Friedman HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.,2/26/2009, (-) - Cancer Abstract [More ...]

Quinn JA,Jiang SX,Carter J,Reardon DA,Desjardins A,Vredenburgh JJ,Rich JN,Gururangan S,Friedman AH,Bigner DD,Sampson JH,McLendon RE,Herndon JE 2nd,Threatt S,Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.,2/1/2009, (1064-8) - Clinical cancer research : an official journal of the American Association for Cancer Research Abstract [More ...]

Desjardins A,Reardon DA,Herndon JE 2nd,Marcello J,Quinn JA,Rich JN,Sathornsumetee S,Gururangan S,Sampson J,Bailey L,Bigner DD,Friedman AH,Friedman HS,Vredenburgh JJ. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas.,11/1/2008, (7068-73) - Clinical cancer research : an official journal of the American Association for Cancer Research Abstract [More ...]

Gururangan S,Krauser J,Watral MA,Driscoll T,Larrier N,Reardon DA,Rich JN,Quinn JA,Vredenburgh JJ,Desjardins A,McLendon RE,Fuchs H,Kurtzberg J,Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.,8/28/2008, (-) - Neuro-oncology Abstract [More ...]

Fouladi M,Chintagumpala M,Ashley D,Kellie S,Gururangan S,Hassall T,Gronewold L,Stewart CF,Wallace D,Broniscer A,Hale GA,Kasow KA,Merchant TE,Morris B,Krasin M,Kun LE,Boyett JM,Gajjar A. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.,8/1/2008, (3749-55) - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Abstract [More ...]


 

Printer Friendly Page Send this Story to a Friend